Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.

In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.

Pharmacists can improve cardiometabolic adherence by easing adverse effects, simplifying regimens, tackling costs, and synchronizing refills.

In this episode, our hosts examine the expanding role of incretin therapies in children and adolescents with obesity and type 2 diabetes.

GLP-1 adherence requires integrated care teams, administrative technology, and proactive clinical support to tackle complex challenges.

Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.

A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.

Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.